Emerging Drugs for Residual CV Risk in Statin-Treated Adults Emerging Drugs for Residual CV Risk in Statin-Treated Adults
Learn about the many novel therapeutics recently approved or under development which target LDL-C and/or triglycerides via different mechanisms than do statins.American Journal of Cardiovascular Drugs
Authors: Xu Y, Hu H, Li Y, Cen R, Yao C, Ma W, Huang M, Yin Y, Gao H, Liu Y, Endler A Abstract Context: Huoxin formula is a Traditional Chinese Medicine for coronary heart disease (CHD) treatment. Objective: To explore the therapeutic mechanism of the Huoxin formula on arterial functions in CHD patients. Materials and methods: Fifty-eight CHD patients receiving cardiovascular drugs including β-receptor blocker, statins, and antiplatelet medications or others were randomized into intervention [additionally 13.5 g Huoxin formula granules dissolved in 150 mL warm water per time, twice a day (n&thins...
This study was aimed at assessing the role of H. pylori infection in GERD utilizing a large cohort of patients diagnosed with GERD. Methods and Materials: All patients who underwent gastroscopy for an indication of GERD during the study period between 2015 and 2017 at the EMMS Nazareth Hospital were considered eligible for the study and therefore were included. H. pylori infection was determined by the rapid urease test or histology. Severity of esophagitis was assessed using the Los Angeles classification. Univariate analysis was performed to figure out differences between patients according to H. pylori infection sta...
Commonly prescribed drugs were stolen in Italy and then sold to British pharmacists and hospitals, exposing patients to potentially lethal consequences. Among them is statin rosuvastatin.
CONCLUSIONS: Compared with the nonuse of LT, there may be a hierarchy of residual vascular risk after stroke by non-LDL type and target, while on LT. Particularly, stroke patients with low HDL-C levels on LT may benefit from additional therapeutic strategies to improve their outcomes. PMID: 31189759 [PubMed - as supplied by publisher]
Conclusion: Challenges with using and changing inhalers has meant this market has not followed other high-volume drug classes following patent loss. This is starting to change, with the situation monitored to enhance efficient prescribing alongside continued good quality care. PMID: 31189394 [PubMed - as supplied by publisher]
Conclusion Statin users in primary prevention experiencing myalgia do not have impaired aerobic exercise performance or muscle strength compared to nonmyalgic statin users or control subjects.
Abstract Globally, approximately 20% of the 400 million individuals with diabetes mellitus have diabetic kidney disease (DKD). DKD is associated with higher cardiovascular and all-cause morbidity and mortality, so timely diagnosis and treatment are critical. Screening for early DKD is best done with annual spot urine albumin/creatinine ratio testing, and diagnosis is confirmed by repeated elevation in urinary albumin excretion. Treatment includes management of hyperglycemia, hypertension, hyperlipidemia, and cessation of tobacco use. Multiple antihyperglycemic medications, including sodium-glucose cotransporter-2 ...
ConclusionsReal-world FAERS data do not raise concern for muscular toxicity with DPP4-is in combination with statins, making a drug interaction very unlikely.
ConclusionsOlder age, history of atrial fibrillation and pneumonia are associated with increased risk of influenza-associated in-hospital and 90-day mortality. Statin use may decrease 90-day mortality.
This report examines the findings from the 2017-18 audit. It contains the full key findings, recommendations and new analysis relating to cardiovascular disease (CVD) risk, including new treatment targets showing statin prescriptions for CVD risk reduction